Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 14/20 | 0.64 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | CTSC | P53634 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30050940 | 1.00 | CTSD (0.64) | CTSDMMEECE1FNTAFNTB | |
| SCHEMBL30052924 | 0.95 | CTSD (0.64) | CTSDMMECTSCACECPA1 | |
| SCHEMBL30050842 | 0.95 | CTSD (0.60) | CTSDMMEECE1CTSCACE | |
| SCHEMBL31462339 | 0.95 | CTSD (0.60) | CTSDMMEECE1CTSCACE | |
| SCHEMBL3052110 | 0.95 | CTSD (0.57) | CTSDMMEECE1CTSCACE | |
| SCHEMBL3052108 | 0.95 | CTSD (0.57) | CTSDMMEECE1CTSCACE | |
| SCHEMBL30051660 | 0.91 | CTSD (0.55) | CTSDMMEFNTAFNTBCTSC | |
| SCHEMBL30974364 | 0.90 | CTSD (0.54) | CTSDMMEACECPA1ACE2 | |
| SCHEMBL29720334 | 0.90 | CTSD (0.53) | CTSDMMEECE1CTSCACE | |
| SCHEMBL30051265 | 0.90 | CTSD (0.53) | CTSDMMEECE1CTSCACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | CTSD 147/4885MME 224/4885ECE1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.